Results 101 to 110 of about 4,101 (234)

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma [PDF]

The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi).
Chen J. M. H., Dreyling M., Eyre T. A., Fischer L., Gine E., Hess G., Jerkeman M., Jimenez-Ubieto A., Keeping S., Lambert J., Linton K., Nunes A., Oberic L., Ohler A., Park J. E., Reitan J., Salles G., Sancho J. -M., Stilgenbauer S., Thieblemont C., Vilmar A., Wade S. W., Wu J. J., Zilioli V. R., Zinzani P. L.   +24 more
core   +1 more source

Poster: CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL

, 2022
Emily Bryer, Shira Paul, Jonathan Chen, Christopher Pleyer, Adrian Wiestner, Clare Sun   +5 more
openalex   +2 more sources

BTKi +humanized anti-CD20 for advanced follicular lymphoma: ready for an ALTERNATIVE?

Haematologica
Not available.
Irene Dogliotti, Massimo Federico
openaire   +2 more sources

P112 | REAL-WORLD OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH BTK INHIBITORS WHO DISCONTINUED TREATMENT FOR REASONS OTHER THAN DISEASE PROGRESSION: EXPERIENCE FROM PIEDMONT CENTERS

Haematologica
Background: The advent of Bruton's tyrosine kinase inhibitors (BTKi) has revolutionized the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). BTKi are administered continuously until progression or unacceptable toxicity.
M. Bullo, D. Cilloni, C. Vitale, F. Perutelli, G. Catania, M. Nicolosi, M. Canepari, D. Gottardi   +7 more
doaj  

A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial [PDF]

SummaryBackground Chronic lymphocytic leukaemia is the commonest leukaemia and is associated with profoundimmunosuppression. Bruton tyrosine kinase inhibitors (BTKi) have revolutionised chronic lymphocytic leukaemiamanagement; however, therapy impairs ...
Hutchinson, Claire, Parry, Helen M.
core   +8 more sources

Off-axis impact of unidirectional composites with cracks: Dynamic stress intensification [PDF]

The dynamic response of unidirectional composites under off axis (angle loading) impact is analyzed by assuming that the composite contains an initial flaw in the matrix material.
Chen, E. P., Sih, G. C.
core   +1 more source

Correlation between Real-World Progression-Free Survival (rwPFS) and Overall Survival (OS) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Relapsed or Are Refractory, Intolerant, Resistant to Treatment with a Bruton's Tyrosine Kinase Inhibitor (BTKi) [PDF]

, 2023
Kevin Lin, Lynn Huynh, Xiaoqin Yang, Enrico Zanardo, Lisa Matay, Megan Pinaire, Daria Liborski, Mikaela M. McDonough, Jillian Foreman, Mohammed Z.H. Farooqui, Enrico De Nigris, Shravanthi R. Gandra, Eric Sarpong, Mei Sheng Duh, Jennifer R. Brown, Matthew S. Davids   +15 more
openalex   +1 more source

Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia

HemaSphere
Our findings provide a snapshot of the current therapeutic landscape in WM after cBTKi failure. Importantly, although none of the baseline disease characteristics influenced response to cBTK‐S, the sample size is too small to make any powered evaluation. On this basis, there is an urgent need for approval in this setting.
Anna Maria Frustaci, Arianna Zappaterra, Andrea Galitzia, Andrea Visentin, Michele Merli, Rita Rizzi, Isacco Ferrarini, Simone Ferrero, Vanessa Innao, Claudia Baratè, Pierluigi Zinzani, Benedetta Puccini, Francesco Autore, Monica Tani, Angela Ferrari, Gioacchino Catania, Maura Nicolosi, Raffaella Pasquale, Marina Motta, Roberta Murru, Silvia Gambara, Francesca Rezzonico, Marzia Varettoni, Emanuele Cencini, Enrico Lista, Nicolò Danesin, Bianca Maria Granelli, Marina Deodato, Francesco Piazza, Alessandra Tedeschi   +29 more
openaire   +8 more sources

P1110: REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)

, 2023
Bijal Shah, Mei Xue, Keri Yang, Sizhu Liu, Boxiong Tang   +4 more
openalex   +1 more source

Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma [PDF]

, 2017
Cerchione, Claudio, Ciancia, Giuseppe, DELLA PEPA, Roberta, DI PERNA, Maria, Giordano, Claudia, Intrieri, Mariano, Pane, Fabrizio, Picardi, Marco, Pugliese, Novella, Raimondo, Marta, Troncone, Giancarlo, Zacheo, Irene   +11 more
core   +1 more source